RecruitingPhase 3NCT04108156
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Studying Central retinal vein occlusion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab(drug)
- Enrollment
- 634 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
- Retinal Consultants of Arizona;Opthalmology, Phoenix, Arizona, United States
- Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
- Associated Retina Consultants, Phoenix, Arizona, United States
- California Retina Consultants, Bakersfield, California, United States
- Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
- The Retina Partners, Encino, California, United States
- Retina Consultants of Orange County;Clinical Research, Fullerton, California, United States
- Jules Stein Eye Institute/ UCLA, Los Angeles, California, United States
- Northern California Retina-Vitreous Associates, Mountain View, California, United States
- East Bay Retina Consultants, Oakland, California, United States
- Doheny Eye Institute, Pasadena, California, United States
- California Eye Specialists Medical Group, Pasadena, California, United States
- Retina Consultants Medical Group, Sacramento, California, United States
- Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04108156 on ClinicalTrials.govOther trials for Central retinal vein occlusion
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07456826Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsHarrow Inc
- ENROLLING BY INVITATIONNANCT07318428AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and GlaucomaInje University
- RECRUITINGNCT07308639DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.Bayer
- RECRUITINGPHASE2NCT07259928Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein OcclusionAnnexin Pharmaceuticals AB
- RECRUITINGEARLY PHASE1NCT04008121Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein SodiumMediBeacon
- RECRUITINGNCT07550777Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal BevacizumabAtaturk University
- RECRUITINGPHASE2NCT07205887A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOEyeBiotech Ltd.
- RECRUITINGNANCT07002372Effect of Video Viewing on Intravitreal Injection ExperienceSecond Affiliated Hospital, School of Medicine, Zhejiang University